How past transient viremia shape natural killer cells’ antibody-dependent functions in youth with perinatal HIV Authors: Arianna Rotili, Chiara Pighi, Alessandro Pucci, Alessia Neri, Giuseppe Rubens Pascucci, Nicole Colantoni, Stefania Bernardi, Elena Morrocchi, Federica Betto, Silvia Di Cesare, Donato Amodio, Mathias Lichterfeld, Nicola Cotugno, Paolo Palma Published: 2026 ABSTRACT SummaryDespite effective antiretroviral therapy, people living with HIV (PLWH) may experience transient viremia episodes, which may impact Natural Killer (NK) cell antibody-dependent cellular cytotoxicity (ADCC). This study aimed to assess ADCC in youth with perinatal HIV compared with healthy controls (HC) and in relation to prior viremia. 22 PLWH were stratified by virological history and assessed during viral suppression. Peripheral blood mononuclear cells were stimulated with HIV+8E5LAV cells with autologous or heterologous HIV plasma to assess ADCC by multicolor flow cytometry. PLWH showed reduced ADCC compared with HC. PLWH with multiple prior viremia episodes showed increased antibody-dependent NK degranulation and a trend toward higher IFN-γ production upon autologous plasma stimulation, without impaired intrinsic NK ADCC capability in response to heterologous plasma. These findings suggest that transient exposure to autologous virus may enhance ADCC in PLWH, supporting further investigation of its potential relevance for HIV remission strategies in larger independent cohorts. Introduction HIV-1 leads to profound alterations of the immune system, beginning in the earliest stages of infection.1,2 In people living with HIV (PLWH), who acquired the virus perinatally, long-term antiretroviral therapy (ART) and sustained virological suppression often lead to only partial restoration of immune function, frequently resulting in suboptimal T cell recovery.3,4,5 Affected immune components include natural killer (NK) cells, which are crucial in antiviral defense,6,7,8,9 by eliminating infected cells via both “natural killing” and FcγRIIIa/CD16-mediated antibody-dependent cellular cytotoxicity (ADCC).10,11 They also contribute to adaptive immune regulation through cytokine production and interactions with dendritic cells.11,12 HIV-1 infection disrupts NK cell subset distribution and impairs their antiviral functions13,14; however, ART long-term viral suppression partially restores these alterations.15 Under physiological conditions, NK cells constitute approximately 5–15% of circulating lymphocytes and can be classified into distinct functional subsets based on CD56 and CD16 lineage marker expression.16 These subsets include the regulatory CD56brightCD16-, the cytotoxic CD56dimCD16+,17,18 and the functionally anergic CD56lowCD16+ subset, often expanded in chronic viral infections, such as HIV.14,17,19 CD16 engagement triggers cytotoxic activity and induces the secretion of pro-inflammatory cytokines and chemokines.20,21,22 Increasing evidence highlights ADCC as a critical component of effective immune responses against HIV. It has been associated with vaccine-induced protection, as evidenced by its contribution to protective efficacy, control of viral replication, and delayed disease progression.15,23,24,25,26 Despite effective ART, transient viremia can be detected in PLWH, often due to unplanned treatment interruptions related to poor adherence. In addition, it has been shown that spontaneous viral transcription can also occur, contributing to transient viremia independently of adherence.27 The exposure to the autologous virus has been correlated with the reinforcement of HIV-specific immunity, particularly cytotoxic CD8+ T cells, the induction of HIV-specific antibodies (Abs), and a subsequent delay in viral rebound.27,28,29,30,31,32,33 Nevertheless, the specific role of NK ADCC in this setting remains poorly defined. This study aims to investigate whether, in perinatally acquired, ART-treated PLWH under long-term virological control, a brief exposure to autologous virus followed by re-establishment of viral suppression may enhance HIV-specific ADCC responses, improving NK cell-mediated cytotoxicity. To address this objective, PLWH were stratified according to the total number of lifetime episodes of detectable viremia. Our findings provide preliminary insights into the immunological impact of transient viremia in virologically suppressed individuals, suggesting that limited viral exposure may be associated with enhanced NK ADCC and warrant further investigation in larger independent cohorts. Results Clinical and demographic features of study participants The clinical and demographic characteristics of the 22 perinatally acquired PLWH included in the study were analyzed (Table 1). The mean age of PLWH was 14.45 ± 6.2 years; 8 participants were male (M) and 14 female (F). ART was initiated at a mean age of 10.13 ± 12.2 months and administered for a mean of 13.6 ± 6.2 years. At sampling, all participants were receiving combination ART, comprising drugs from four classes: nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase inhibitor (II), and protease inhibitor (PI). HIV-specific IgG responses were characterized using the HIV western blot 2.2 assay34 and were heterogeneous across study participants. Reactivity against Env proteins (gp160, gp120, gp41) and the Gag antigen p24 was most frequently observed, whereas responses to Pol-derived antigens were less consistently detected. Reactivity patterns for all HIV antigens tested and cumulative western blot (WB) scores across all study participants are reported in Table S1. The average cumulative WB score among PLWH was 1.727 ± 1.7. Regarding cytomegalovirus (CMV) serostatus, 68.2% of PLWH were CMV+, and episodes of detectable VL over time were observed in 59.1% of participants.Table 1Demographic, clinical and NK cell phenotype characteristics of perinatally acquired PLWH and HC study participants and within perinatally acquired PLWH stratified by episodes of detectable VLPLWH (N = 22)HC (N = 8)p valueDet VL = 0 (N = 9)Det VL = 1 (N = 10)Det VL ≥ 2 (N = 3)p valueMale (%)36.4%50%ns66.7%20%0%nsAge (years)14.45 ± 6.226.84 ± 3.8<0.000112.18 ± 5.415.29 ± 5.918.46 ± 8.1nsEthnicity (%) black50%0%0.005333.3%70%33.3%ns white36.4%100%55.6%20%33.3% other13.6%0%11.1%10%33.3%Age at ART start (months)10.13 ± 12.2N/A–8.45 ± 7.210.13 ± 16.615.21 ± 8.2nsTime on ART (years)13.6 ± 6.2N/A–11.48 ± 5.4214.45 ± 5.7317.2 ± 9.7nsEpisodes of detectable VL (%)a none40.9%N/A–100%0%0%– blip18.2%30%33.3% spike27.3%50%33.3% rebound13.6%10%66.7% virological failure18.2%10%100%ART groups at enrollment (n)b6(NRTI_NNRTI)N/A–2(NRTI_NNRTI)3(NRTI_NNRTI)1(NRTI_NNRTI)ns5(NRTI_PI)3(NRTI_PI)1(NRTI_PI)1(NRTI_PI)2(2NRTI_PI)–2(2NRTI_PI)–3(3NRTI)2(3NRTI)1(3NRTI)–3(2NRTI_1NNRTI)–2(2NRTI_1NNRTI)1(2NRTI_1NNRTI)1(NRTI_II)–1(NRTI_II)–1(3NRTI_1NNRTI)1(3NRTI_1NNRTI)––1(2NRTI_1NNRTI_PI)1(2NRTI_1NNRTI_PI)––WB score1.727 ± 1.7N/A–1.55 ± 1.41.2 ± 1.54 ± 1.8nsCMV serostatus (%)68.2%50%ns77%60%66%nsNK frequencies (%) NK cells4.435 ± 2.313.67 ± 4.40.00015 ± 2.43.98 ± 2.93.68 ± 0.3ns CD56dimCD16-8.408 ± 5.63.24 ± 1.50.00968.09 ± 5.610 ± 7.66.2 ± 1.2ns CD56brightCD16-13.42 ± 7.75.92 ± 4.40.0212.43 ± 9.214.15 ± 5.314.93 ± 11.1ns CD56brightCD16+6.097 ± 2.74.21 ± 2.0ns6.04 ± 2.55.84 ± 2.66.75 ± 5.3ns CD56dimCD16+58.29 ± 11.183.7 ± 6.90.000161 ± 13.755.1 ± 5.256.6 ± 15.8ns CD56lowCD16+11.9 ± 3.33.0 ± 1.3<0.000110.25 ± 3.412.9 ± 2.114.8 ± 3.4nsValues are expressed as mean ± SD unless otherwise stated. NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; II: integrase inhibitor; PI: protease inhibitor. Statistical analyses were performed using the Mann-Whitney U test and Kruskal-Wallis test for comparison between two or three independent groups, respectively. Fisher’s exact test was used for categorical variables. Statistical significance was defined as p < 0.05.aSome participants had more than one.bAll participants took a combination of drugs. Table 1Demographic, clinical and NK cell phenotype characteristics of perinatally acquired PLWH and HC study participants and within perinatally acquired PLWH stratified by episodes of detectable VLPLWH (N = 22)HC (N = 8)p valueDet VL = 0 (N = 9)Det VL = 1 (N = 10)Det VL ≥ 2 (N = 3)p valueMale (%)36.4%50%ns66.7%20%0%nsAge (years)14.45 ± 6.226.84 ± 3.8<0.000112.18 ± 5.415.29 ± 5.918.46 ± 8.1nsEthnicity (%) black50%0%0.005333.3%70%33.3%ns white36.4%100%55.6%20%33.3% other13.6%0%11.1%10%33.3%Age at ART start (months)10.13 ± 12.2N/A–8.45 ± 7.210.13 ± 16.615.21 ± 8.2nsTime on ART (years)13.6 ± 6.2N/A–11.48 ± 5.4214.45 ± 5.7317.2 ± 9.7nsEpisodes of detectable VL (%)a none40.9%N/A–100%0%0%– blip18.2%30%33.3% spike27.3%50%33.3% rebound13.6%10%66.7% virological failure18.2%10%100%ART groups at enrollment (n)b6(NRTI_NNRTI)N/A–2(NRTI_NNRTI)3(NRTI_NNRTI)1(NRTI_NNRTI)ns5(NRTI_PI)3(NRTI_PI)1(NRTI_PI)1(NRTI_PI)2(2NRTI_PI)–2(2NRTI_PI)–3(3NRTI)2(3NRTI)1(3NRTI)–3(2NRTI_1NNRTI)–2(2NRTI_1NNRTI)1(2NRTI_1NNRTI)1(NRTI_II)–1(NRTI_II)–1(3NRTI_1NNRTI)1(3NRTI_1NNRTI)––1(2NRTI_1NNRTI_PI)1(2NRTI_1NNRTI_PI)––WB score1.727 ± 1.7N/A–1.55 ± 1.41.2 ± 1.54 ± 1.8nsCMV serostatus (%)68.2%50%ns77%60%66%nsNK frequencies (%) NK cells4.435 ± 2.313.67 ± 4.40.00015 ± 2.43.98 ± 2.93.68 ± 0.3ns CD56dimCD16-8.408 ± 5.63.24 ± 1.50.00968.09 ± 5.610 ± 7.66.2 ± 1.2ns CD56brightCD16-13.42 ± 7.75.92 ± 4.40.0212.43 ± 9.214.15 ± 5.314.93 ± 11.1ns CD56brightCD16+6.097 ± 2.74.21 ± 2.0ns6.04 ± 2.55.84 ± 2.66.75 ± 5.3ns CD56dimCD16+58.29 ± 11.183.7 ± 6.90.000161 ± 13.755.1 ± 5.256.6 ± 15.8ns CD56lowCD16+11.9 ± 3.33.0 ± 1.3<0.000110.25 ± 3.412.9 ± 2.114.8 ± 3.4nsValues are expressed as mean ± SD unless otherwise stated. NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; II: integrase inhibitor; PI: protease inhibitor. Statistical analyses were performed using the Mann-Whitney U test and Kruskal-Wallis test for comparison between two or three independent groups, respectively. Fisher’s exact test was used for categorical variables. Statistical significance was defined as p < 0.05.aSome participants had more than one.bAll participants took a combination of drugs. Demographic, clinical and NK cell phenotype characteristics of perinatally acquired PLWH and HC study participants and within perinatally acquired PLWH stratified by episodes of detectable VL Values are expressed as mean ± SD unless otherwise stated. NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; II: integrase inhibitor; PI: protease inhibitor. Statistical analyses were performed using the Mann-Whitney U test and Kruskal-Wallis test for comparison between two or three independent groups, respectively. Fisher’s exact test was used for categorical variables. Statistical significance was defined as p < 0.05. Some participants had more than one. All participants took a combination of drugs. Longitudinal evaluation of virological history showed that the median time between documented virological suppression and transient viremia was 6.35 months (IQR: 2.9–8.5), while the median interval between transient viremia and renewed suppression was 3.4 months (IQR: 2.5–3.8). Importantly, episodes of transient viremia occurred a median of 6.77 years (IQR: 2.8–9.7) prior to PBMC and plasma sample collection used for immunological analyses, suggesting that the observed antibody-dependent NK cell features are more likely associated with long-term immune imprinting. The perinatally acquired PLWH cohort was compared with HCs (mean age: 26.84 ± 3.8 years; 4M and 4F) (Table 1). No significant differences in sex distribution and CMV serostatus were observed between groups. PLWH were significantly younger than HCs (Mann-Whitney U test: U = 15, p < 0.0001), and ethnicity distribution also differed (Fisher’s exact test: p = 0.0053), as all HCs were white. Among perinatally acquired PLWH stratified according to virological history, no significant differences in age or sex distribution were observed (Table 1). In addition, 4 viremic individuals with perinatal HIV (vPLWH, 1M and 3F) were included in the analysis. They had a mean age of 22.32 ± 4.50 years, initiated ART at a mean age of 65.5 ± 94.3 months, for a mean of 16.86 ± 8.0 years, and were on 2NRTIs+II ART regimen. The mean WB score was 8.38 ± 0.9. All vPLWH were CMV+ and experienced episodes of detectable VL over time. HIV infection impacts on NK cell compartment Compared to perinatally acquired PLWH, HC exhibited significantly higher frequencies of both total NK cells and the cytotoxic CD56dimCD16+ population (Mann-Whitney U test: U = 3, p = 0.0001 for both). The gating strategy is shown in Figure S1A. In contrast, PLWH showed a significant expansion of the CD56dimCD16- (Mann-Whitney U test: U = 15, p = 0.0096), CD56brightCD16- (Mann-Whitney U test: U = 18, p = 0.02) and CD56lowCD16+ (Mann-Whitney U test: U = 0, p < 0.0001) subsets (Table 1), consistent with prior studies.14,17,19 This phenotypic profile indicates that perinatally acquired PLWH maintain persistent alterations in NK cell subset distribution despite long-term suppressive ART. Among PLWH stratified according to events of detectable VL, no significant differences were observed in total NK cell frequencies or subset distribution (Table 1). Interestingly, although perinatally acquired vPLWH displayed a comparable reduction in total NK cells, their subset composition differed, with a marked expansion of the CD56lowCD16+ population at the expense of all other subsets. NK-mediated ADCC is enhanced in HC compared to perinatally acquired PLWH ADCC was quantified as fold changes in the frequency or MFI of NK functional markers, measured as the ratio between plasma- and no plasma-stimulated conditions. Ab-mediated NK functions were assessed by comparing perinatally acquired PLWH and HC under different stimulation conditions (Figure 1A). The ADCC assay setup and gating strategy are detailed in Figure S1B. Under heterologous HIV+ plasma (pHIVhetero) stimulation, HC exhibited significantly higher frequencies of CD107a+ and CD107a+IFN-γ- NK cells (Mann-Whitney U test: U = 40, p = 0.043 for both) compared with PLWH. In PLWH, pHIVhetero induced a significantly greater fold increase in CD107a+ (Friedman test, χ2(2) = 21.1, p < 0.0001) and CD107a+IFN-γ- (Friedman test, χ2(2) = 22.8, p < 0.0001) NK cells than HIV- plasma (pHD) (uncorrected Dunn’s test: Z = 4.58, p < 0.0001 and uncorrected Dunn’s test: Z = 4.74, p < 0.0001 respectively) and autologous HIV+ plasma (pHIVauto) (uncorrected Dunn’s test: Z = 2.53, p = 0.011 and uncorrected Dunn’s test: Z = 2.85, p = 0.004, respectively). Conversely, the frequency of CD107a-IFN-γ- NK cells (Friedman test, χ2(2) = 22.8, p < 0.0001) was significantly reduced upon pHIVhetero compared with pHD (uncorrected Dunn’s test: Z = 4.74, p < 0.0001) and pHIVauto (uncorrected Dunn’s test: Z = 2.85, p = 0.004). A significant increase in CD107a+ NK cells was also observed following pHIVauto stimulation compared with pHD (uncorrected Dunn’s test: Z = 2.055, p = 0.04). Similarly, in HC, pHIVhetero resulted in significantly increased frequencies of CD107a+, IFN-γ+, CD107a+IFN-γ- and CD107a+IFN-γ+ NK cells (Wilcoxon test: W = 36, p = 0.008 for all), accompanied by a significant decrease in CD107a-IFN-γ- NK cells (Wilcoxon test: W = −36, p = 0.008) compared with pHD. As expected, stimulation with pHD elicited minimal responses across all groups (Figure 1A). CD16 surface downregulation, indicative of Ab-mediated NK activation, was observed in both PLWH (Friedman test, χ2(2) = 27.3, p < 0.0001) and HC following pHIVhetero stimulation compared with pHD (uncorrected Dunn’s test: Z = 4.74, p < 0.0001 and Wilcoxon test: W = −36, p = 0.008, respectively). A significant downmodulation of CD16 was also observed following pHIVhetero stimulation compared with pHIVauto (uncorrected Dunn’s test: Z = 4.27, p < 0.0001) in PLWH. Interestingly, HCs displayed significantly lower CD16 expression under pHIVhetero than PLWH (Mann-Whitney U test: U = 37, p = 0.028) (Figure 1B). To further clarify whether differences in CD16 modulation during antibody-dependent stimulation could be influenced by baseline receptor expression, CD16 surface levels were evaluated across study groups. HC exhibited significantly higher baseline CD16 expression (Mann-Whitney U test: U = 15, p = 0.0002) compared to PLWH (Figure S2A, left image).Figure 1NK-mediated ADCC, CD16 expression, and target killing in perinatally acquired PLWH and HCBar plots (median ± IQR) show (A) the fold increase (fi) in activated NK cell populations between plasma (PLWH pHD, light gray; HC pHD, light green; PLWH pHIVauto, gray; PLWH pHIVhetero, dark gray; HC pHIVhetero, dark green)-stimulated and unstimulated samples, (B) the fi in CD16 mean fluorescence intensity (MFI) on NK cells, (C) the % of target killing in PLWH (n = 22 in A, B, and D; n = 18 in C) and HC (n = 8 in A, B, and D; n = 6 in C) and (D) the fi in perforin/granzyme B MFI on NK cells. Within-group differences in PLWH were assessed using the Friedman test followed by uncorrected Dunn’s post hoc test. The Wilcoxon signed-rank test was used for paired comparisons in HC. Between-group comparisons were performed using the Mann-Whitney U test. Statistical significance was defined as p < 0.05. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.0099; ∗∗∗ 0.0001 < p < 0.00099; ∗∗∗∗p < 0.0001. NK-mediated ADCC, CD16 expression, and target killing in perinatally acquired PLWH and HC Bar plots (median ± IQR) show (A) the fold increase (fi) in activated NK cell populations between plasma (PLWH pHD, light gray; HC pHD, light green; PLWH pHIVauto, gray; PLWH pHIVhetero, dark gray; HC pHIVhetero, dark green)-stimulated and unstimulated samples, (B) the fi in CD16 mean fluorescence intensity (MFI) on NK cells, (C) the % of target killing in PLWH (n = 22 in A, B, and D; n = 18 in C) and HC (n = 8 in A, B, and D; n = 6 in C) and (D) the fi in perforin/granzyme B MFI on NK cells. Within-group differences in PLWH were assessed using the Friedman test followed by uncorrected Dunn’s post hoc test. The Wilcoxon signed-rank test was used for paired comparisons in HC. Between-group comparisons were performed using the Mann-Whitney U test. Statistical significance was defined as p < 0.05. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.0099; ∗∗∗ 0.0001 < p < 0.00099; ∗∗∗∗p < 0.0001. Target killing assay was performed under the same experimental conditions. A representative cartoon and the gating strategy are shown in Figure S1C. % of killing significantly increased in both PLWH (Friedman test, χ2(2) = 8.6, p = 0.014; uncorrected Dunn’s test: Z = 2.83, p = 0.005) and HC (Wilcoxon test: W = 21, p = 0.03) following pHIVhetero stimulation compared with pHD, with HC exhibiting greater killing activity under pHIVhetero (Mann-Whitney U test: U = 24, p = 0.047) than PLWH (Figure 1C). Intracellular lytic effectors, including perforin and granzyme B, were modulated across stimulation conditions. In HCs, pHIVhetero induced significant enzyme release compared to pHD (Wilcoxon test: W = −36, p = 0.008). In PLWH, a similar trend was observed, with reduced levels of perforin and granzyme B (Friedman test, χ2(2) = 18.3, p = 0.0001) under pHIVhetero compared to both pHD (uncorrected Dunn’s test: Z = 4.27, p < 0.0001) and pHIVauto (uncorrected Dunn’s test: Z = 2.37, p = 0.018) conditions. Accordingly, pHIVhetero-induced lytic mediator levels were higher in HCs than in PLWH (Mann-Whitney U test: U = 34, p = 0.018) (Figure 1D). In perinatally acquired vPLWH, pHIVhetero stimulation also induced significantly higher frequencies of CD107a+ (Friedman test, χ2(2) = 6.5, p = 0.04; uncorrected Dunn’s test: Z = 2.47, p = 0.013) and CD107a+IFN-γ- (Friedman test, χ2(2) = 8, p = 0.005; uncorrected Dunn’s test: Z = 2.83, p = 0.005) NK cells than pHD (Figure S3A). Moreover, pHIVauto induced enhanced ADCC responses, although not significant, reflecting higher levels of HIV-specific Abs, as supported by significantly (Mann-Whitney U test: U = 0, p < 0.0001) higher WB scores in vPLWH compared with PLWH (Figure S3B). Consistent, killing activity was significantly higher under pHIVhetero stimulation than pHD (Friedman test, χ2(2) = 6.5, p = 0.042; uncorrected Dunn’s test: Z = 2.48, p = 0.013) (Figure S3C). To further explore NK cell function independently of antibody-mediated effects, we performed a complementary analysis of natural cytotoxicity against 8E5LAV targets in the absence of plasma. As a target-free control condition was not available, NK cell activation is presented as the absolute frequency of functional NK cell subsets. Despite this limitation, perinatally acquired PLWH exhibited an overall higher frequency of NK cell activation compared to HCs, with a significantly increased proportion of CD107a+ (Mann-Whitney U test: U = 36, p = 0.013) and CD107a+IFN-γ+ (Mann-Whitney U test: U = 44, p = 0.04) NK cells (Figures S2B and S2D, left images). Autologous plasma-induced ADCC correlates with previous transient viremia in virally suppressed perinatally acquired PLWH To explore whether transient episodes of detectable viremia throughout life could enhance ADCC responses in virologically suppressed perinatally acquired HIV individuals, the PLWH cohort was stratified into three groups based on the number of past detectable VL episodes (0; 1; ≥2) (Figure 2A). Plasma samples were collected at a single time point per participant, corresponding to the most recent available sample obtained during sustained virological suppression, to ensure comparability across individuals and reduce confounding effects related to transient clinical variability associated with virological or immunological status. Of note, one participant in the group with no prior viremia episodes was excluded from autologous plasma-based functional analyses due to the unavailability of a matched plasma sample.Figure 2Correlation between NK functional responses to pHIVauto stimulation and clinical variables in perinatally acquired PLWH(A) Schematic cartoon of cohort stratification based on the number of past detectable VL events: 0 (light blue), 1 (blue), and ≥2 (dark blue).(B) Bar plots (median ± IQR) show WB score stratified by the number of detectable VL events.(C) Heatmap displays Spearman’s rank correlation coefficients between NK functional parameters, measured upon pHIVauto stimulation, and two clinical variables: number of past detectable VL episodes and WB score, in PLWH (n = 21). One individual in the VL = 0 group was excluded because no plasma sample matched to the PBMC was available.Color scale represents correlation strength (ranging from −0.4 to 0.4), with intensity proportional to the correlation magnitude.(D) Bar plots (median ± IQR) show NK functional parameters stratified by the number of detectable VL events. Group comparisons were performed using the Kruskal-Wallis H test followed by Dunn’s post hoc test.(E) Linear regression plots illustrate associations between NK functional parameters and WB scores. Statistical significance was defined as p < 0.05. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.0099; ∗∗∗ 0.0001 < p < 0.00099; ∗∗∗∗p < 0.0001. Correlation between NK functional responses to pHIVauto stimulation and clinical variables in perinatally acquired PLWH (A) Schematic cartoon of cohort stratification based on the number of past detectable VL events: 0 (light blue), 1 (blue), and ≥2 (dark blue). (B) Bar plots (median ± IQR) show WB score stratified by the number of detectable VL events. (C) Heatmap displays Spearman’s rank correlation coefficients between NK functional parameters, measured upon pHIVauto stimulation, and two clinical variables: number of past detectable VL episodes and WB score, in PLWH (n = 21). One individual in the VL = 0 group was excluded because no plasma sample matched to the PBMC was available. Color scale represents correlation strength (ranging from −0.4 to 0.4), with intensity proportional to the correlation magnitude. (D) Bar plots (median ± IQR) show NK functional parameters stratified by the number of detectable VL events. Group comparisons were performed using the Kruskal-Wallis H test followed by Dunn’s post hoc test. (E) Linear regression plots illustrate associations between NK functional parameters and WB scores. Statistical significance was defined as p < 0.05. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.0099; ∗∗∗ 0.0001 < p < 0.00099; ∗∗∗∗p < 0.0001. We first examined WB score distribution and, as expected, observed higher levels of HIV-specific Abs in individuals with more prior viremia episodes (Figure 2B). Next, we assessed associations between ADCC functional markers and target killing, measured following pHIVauto stimulation, with both the number of past detectable VL episodes and WB score (Figure 2C). Correlation analysis identified a significant positive association between detectable VL episodes and CD107a+ NK cell frequency (ρ = 0.45; CI_ ρ low: 0.0044; CI_ ρ high: 0.76; p = 0.04), along with a significant inverse correlation with CD107a-IFN-γ- NK cells (ρ = −0.52; CI_ ρ low: −0.78; CI_ ρ high: −0.14; p = 0.017). Additional positive trends were observed with IFN-γ+ (ρ = 0.31; CI_ ρ low: −0.13; CI_ ρ high: 0.68), CD107a+IFN-γ- (ρ = 0.41; CI_ ρ low: −0.011; CI_ ρ high: 0.71) and CD107a+IFN-γ+ (ρ = 0.40; CI_ ρ low: −0.036; CI_ ρ high: 0.73) NK cell subsets, while CD16 expression (ρ = −0.42; CI_ ρ low: −0.76; CI_ ρ high: 0.044) showed a negative trend, consistent with receptor downregulation upon Ab engagement. These associations were further supported by group comparisons, in which participants with ≥2 detectable VL episodes exhibited significantly higher frequency of CD107a+ NK cells (Kruskal-Wallis test: H(2) = 4.9, p = 0.082; uncorrected Dunn’s test: Z = 2.21, p = 0.027), together with a reduced proportion of CD107a-IFN-γ- NK cells (Kruskal-Wallis test: H(2) = 5.36, p = 0.063; uncorrected Dunn’s test: Z = 2.18, p = 0.03) and lower CD16 MFI (Kruskal-Wallis test: H(2) = 4.9, p = 0.082; uncorrected Dunn’s test: Z = 2.2, p = 0.028), compared with fully virologically suppressed individuals (Figure 2D). Although correlations between WB score and NK function did not reach statistical significance, positive trends were noted for CD107a+ (ρ = 0.33, CI_ ρ low: −0.19; CI_ ρ high: 0.76) and CD107a+IFN-γ- (ρ = 0.27, CI_ ρ low: −0.28; CI_ ρ high: 0.65) NK cells, and a negative trend for CD16 (ρ = −0.43, CI_ ρ low: −0.78; CI_ ρ high: 0.085) expression (Figure 2C). Regression analyses (Figure 2E) further showed that higher WB scores were associated with increased frequencies of CD107a+ (R2 = 0.24, p = 0.024) and CD107a+IFN-γ- (R2 = 0.32, p = 0.007) NK cells, as well as decreased CD16 MFI (R2 = 0.30, p = 0.01). All these associations should be interpreted considering the sample size and the exploratory nature of the analysis and require validation in larger independent cohorts. When accounting for baseline CD16 levels, no significant differences were observed within stratified perinatally acquired PLWH. However, individuals with a history of multiple transient viremia episodes tended to exhibit relatively higher baseline CD16 expression compared to those with 0 or 1 prior episode (Figure S2A, middle image). To further explore these findings, 4 perinatally acquired vPLWH were included, and the correlation analysis was repeated across the entire HIV cohort (Figure S3D). Following pHIVauto stimulation, both the number of detectable VL episodes and WB score positively correlated with CD107a+ (ρ = 0.56; CI_ ρ low: 0.21; CI_ ρ high: 0.78; p = 0.004 and ρ = 0.49; CI_ ρ low: 0.12; CI_ ρ high: 0.74; p = 0.012, respectively) and CD107a+IFN-γ- (ρ = 0.53; CI_ ρ low: 0.17; CI_ ρ high: 0.76; p = 0.007 and ρ = 0.45; CI_ ρ low: 0.07; CI_ ρ high: 0.72; p = 0.024, respectively) NK cells, as well as with target killing (ρ = 0.52; CI_ ρ low: 0.13; CI_ ρ high: 0.77; p = 0.013 and ρ = 0.43; CI_ ρ low: 0.015; CI_ ρ high: 0.72; p = 0.044, respectively). Conversely, both parameters were negatively associated with CD107a-IFN-γ- NK cells (ρ = −0.66; CI_ ρ low: −0.84; CI_ ρ high: −0.37; p = 0.0003 and ρ = −0.49; CI_ ρ low: −0.74; CI_ ρ high: −0.11; p = 0.013, respectively) and CD16 expression (ρ = −0.52; CI_ ρ low: −0.76; CI_ ρ high: −0.16; p = 0.008 and ρ = −0.51; CI_ ρ low: −0.76; CI_ ρ high: −0.15; p = 0.008). Detectable VL events were also significantly (ρ = 0.43; CI_ ρ low: 0.041; CI_ ρ high: 0.7; p = 0.032) associated with IFN-γ+ NK cells (Figure S3D). Overall, individuals with ≥2 previous detectable VL episodes displayed significantly higher frequencies of CD107a+ (Kruskal-Wallis test: H(2) = 8.12, p = 0.017; uncorrected Dunn’s test: Z = 2.8, p = 0.006 and Z = 2.1, p = 0.035) and CD107a+IFN-γ- (Kruskal-Wallis test: H(2) = 7, p = 0.03; uncorrected Dunn’s test: Z = 2.6, p = 0.009) NK cells, enhanced target killing (Kruskal-Wallis test: H(2) = 9.4, p = 0.005; uncorrected Dunn’s test: Z = 3, p = 0.0025 and Z = 2.13, p = 0.033) and lower frequencies of CD107a-IFN-γ- NK cells (Kruskal-Wallis test: H(2) = 10.9, p = 0.004; uncorrected Dunn’s test: Z = 3.3, p = 0.001 and Z = 2.1, p = 0.04) and CD16 MFI (Kruskal-Wallis test: H(2) = 7.5, p = 0.024; uncorrected Dunn’s test: Z = 2.6, p = 0.009 and Z = 2.15, p = 0.03), compared with individuals with 0 or 1 prior episode of detectable viremia (Figure S3E). Baseline CD16 levels did not significantly differ across perinatally acquired PLWH, including viremic individuals; however, a trend toward higher baseline CD16 expression in individuals with a history of multiple transient viremia episodes was confirmed (Figure S2A, right image). A complementary analysis of natural cytotoxicity, reported as the absolute frequencies of functional NK cell subsets due to the absence of a target-free control condition, suggested higher overall NK cell activation in PLWH with multiple episodes of detectable viremia compared with those with fewer or no episodes. Specifically, these individuals showed increased frequencies of IFN-γ+ (Kruskal-Wallis test: H(2) = 5, p = 0.078; uncorrected Dunn’s test: Z = 2, p = 0.04 vs. VL = 1) and CD107a-IFN-γ+ NK cells (Kruskal-Wallis test: H(2) = 6.3, p = 0.035; uncorrected Dunn’s test: Z = 2.5, p = 0.013 vs. VL = 1), together with a reduced frequency of the CD107a-IFN-γ- subset (Kruskal-Wallis test: H(2) = 4.8, p = 0.088; uncorrected Dunn’s test: Z = 2, p = 0.047 vs. VL = 1) (Figures S2C, S2F, and S2G, middle images). This trend was further accentuated when viremic individuals were included in the VL ≥2 group, which displayed a broader increase in effector NK subsets, including CD107a+ (Kruskal-Wallis test: H(2) = 5, p = 0.08; uncorrected Dunn’s test: Z = 2.2, p = 0.02), IFN-γ+ (Kruskal-Wallis test: H(2) = 6.6, p = 0.04; uncorrected Dunn’s test: Z = 2.5, p = 0.012) NK cells compared to VL = 1, along with a reduction in non-responsive NK cells (Kruskal-Wallis test: H(2) = 7.3, p = 0.027; uncorrected Dunn’s test: Z = 2.7, p = 0.0075 vs. VL = 1) (Figures S2B, S2C, and S2G, right images). Prior viremia does not affect NK ADCC upon heterologous plasma stimulation in perinatally acquired PLWH To explore whether episodes of detectable viremia and WB score influence intrinsic Ab-dependent NK functionality, we evaluated ADCC-related markers and target killing following stimulation with standardized heterologous HIV+ plasma in stratified perinatally acquired PLWH groups. As shown in Figure 3A, the correlation heatmap revealed no significant associations between WB score and NK functional parameters under these conditions. The number of prior detectable viremia episodes showed modest, not statistically significant, associations with certain ADCC-related readouts: IFN-γ+ (ρ = 0.34, CI_ ρ low: −0.036; CI_ ρ high: 0.65), CD107a+IFN-γ+ (ρ = 0.37, CI_ ρ low: −0.036; CI_ ρ high: 0.68), CD107a-IFN-γ- (ρ = −0.39, CI_ ρ low: −0.68; CI_ ρ high: −0.002) NK cells and killing (ρ = 0.35, CI_ ρ low: −0.16; CI_ ρ high: 0.77). Specifically, individuals with 1 prior episode of detectable viremia exhibited slightly higher frequencies of IFN-γ+ NK cells, either alone or co-expressing CD107a, while individuals with ≥2 past episodes tended to show increased target killing compared with those who remained persistently aviremic. Moreover, a trend toward an inverse correlation was observed between CD107a-IFN-γ- NK cell frequency and viremia history (Figure 3B). Despite these subtle differences, NK cell responses to heterologous stimulation appeared largely comparable across all groups, suggesting that intrinsic Ab-dependent NK functionality is not substantially affected by prior viremia or the presence of circulating HIV-specific Abs under these experimental conditions.Figure 3Correlation between NK functional responses to pHIVhetero stimulation and clinical variables in perinatally acquired PLWH(A) Heatmap showing Spearman’s rank correlation coefficients between NK cell functional parameters, measured upon pHIVhetero stimulation, and number of past detectable VL episodes and WB score, in PLWH (n = 22). The color scale represents the strength of the correlation (ranging from −0.4 to 0.4), with intensity proportional to the correlation magnitude.(B) Bar plots (median ± IQR) depict NK functional responses stratified by the number of detectable VL events: 0 (light blue), 1 (blue), and ≥2 (dark blue). Group comparisons were performed using the Kruskal-Wallis H test followed by Dunn’s post hoc test. Statistical significance was defined as p < 0.05. Correlation between NK functional responses to pHIVhetero stimulation and clinical variables in perinatally acquired PLWH (A) Heatmap showing Spearman’s rank correlation coefficients between NK cell functional parameters, measured upon pHIVhetero stimulation, and number of past detectable VL episodes and WB score, in PLWH (n = 22). The color scale represents the strength of the correlation (ranging from −0.4 to 0.4), with intensity proportional to the correlation magnitude. (B) Bar plots (median ± IQR) depict NK functional responses stratified by the number of detectable VL events: 0 (light blue), 1 (blue), and ≥2 (dark blue). Group comparisons were performed using the Kruskal-Wallis H test followed by Dunn’s post hoc test. Statistical significance was defined as p < 0.05. Discussion In this study, we explored whether transient detectable viremia, followed by sustained viral suppression, influences NK-mediated ADCC in ART-treated children and young adults with perinatal HIV. While the effects of transient antigen exposure have been extensively characterized in the context of adaptive immunity, particularly in shaping HIV-specific CD8+ T cell responses,33,35 their impact on innate immune functions, especially NK cell-mediated ADCC, remains less well defined. A key strength of this study lies in the use of a robust, standardized ADCC assay system, originally developed by Lee et al.36,37 and refined by our group,38 enabling a comprehensive functional assessment of HIV-specific NK responses in both autologous and heterologous contexts. 8E5LAV target cell line is a well-established model for the assessment of HIV-specific ADCC responses in the context of limited pediatric samples and well-controlled infection.38 This cell line expresses multiple HIV-1 structural proteins,39 thereby providing a broadly representative antigenic substrate for antibody-mediated recognition that would be expected against infected cells during in vivo antigen exposure. Study participants were stratified based on the number of past detectable VL events. Despite long-term suppressive ART, perinatally acquired PLWH exhibited significant alterations in the NK cell compartment compared with HC. Indeed, phenotypic analysis revealed a shift toward immature and dysfunctional NK cells, consistent with previous findings.9,14,19,40 In particular, PLWH displayed an expansion of the CD56dimCD16- heterogeneous population, which includes both immature and differentiated cytokine-producing NK cells,9,41 and of the anergic CD56lowCD16+ subset,14,17,19 indicating persistent perturbation of NK cell maturation and functionality. Concurrently, the reduction of cytotoxic CD56dimCD16+ cells42,43 likely contributes to the diminished ADCC responses observed in PLWH, in contrast to the more preserved NK cell repertoire in HC. As previously reported, perinatally acquired vPLWH displayed broader contraction of most NK subsets except for CD56lowCD16+ cells, which were selectively expanded,14,17,19 suggesting that ongoing viremia impairs NK cell development and function that are only partially restored by ART.15,44 To investigate whether prior transient episodes of detectable viremia in otherwise virologically suppressed perinatally acquired PLWH may influence ADCC, we analyzed NK functional markers following stimulation with autologous plasma and their association with clinical parameters. Higher NK ADCC responses were observed in participants with ≥2 prior viremia episodes, reflected by increased frequencies of degranulating NK cells and a concomitant reduction in non-responding cells, compared with individuals without prior viremia. Reduced CD16 expression in these participants likely reflects receptor downregulation due to plasmatic Ab engagement. Indeed, these individuals exhibited higher WB scores, supporting a possible link between previous antigen exposure and broader HIV-specific Ab responses. To investigate whether the elevated ADCC observed in participants with ≥2 prior episodes of detectable viremia was attributable to enhanced intrinsic Ab-dependent cytotoxic potential of NK cells, we assessed responses in the stratified perinatally acquired PLWH cohort following stimulation with a standardized heterologous HIV+ plasma. Under these conditions, no significant associations were observed between WB score and NK functional markers, suggesting that Ab breadth or affinity maturation alone may not fully account for NK responsiveness. While prior detectable VL episodes showed modest correlations with certain ADCC readouts, NK cell responses appeared largely comparable across groups, indicating that intrinsic Ab-dependent NK cell functionality may not be substantially affected by prior viremia, circulating HIV-specific Abs, or chronic CD16 engagement. Although limited by the small sample size, overall, these findings are consistent with the hypothesis that HIV-specific Abs, rather than major intrinsic NK perturbations, may contribute to the enhanced ADCC observed in perinatally acquired PLWH who experienced multiple, resolved episodes of detectable viremia. This distinguishes our findings from CMV-driven adaptive NK cells or cytokine-induced memory-like NK cells,45,46,47 both of which rely on durable cell-intrinsic functional and epigenetic remodeling.48,49 To further explore these findings, we included 4 perinatally acquired vPLWH with a history of long-term viral suppression and higher WB scores, and reassessed correlations across the entire cohort. Upon autologous plasma stimulation, both the number of past detectable VL episodes and WB score positively correlated with frequencies of degranulating or IFN-γ producing NK cells and with target killing, whereas CD16 expression and the frequency of non-responding NK cells were inversely associated. Importantly, the groups displaying the strongest ADCC responses and the greatest CD16 downregulation following antibody-dependent stimulation also showed relatively higher baseline CD16 expression, suggesting that receptor modulation reflects dynamic engagement and internalization/shedding during ADCC. To have a broader view of the impact of transient viremia on NK cell functionality independently of antibody-mediated effects, we performed a complementary analysis of natural cytotoxicity against 8E5LAV targets in the absence of plasma. As a target-free control condition could not be included because of the limited samples’ availability, these findings should be considered exploratory. In this setting, perinatally acquired PLWH with a higher number of prior transient viremia episodes displayed increased baseline NK cell functional activity, characterized by higher IFN-γ production and natural cytotoxicity. However, these differences did not translate into enhanced ADCC upon stimulation with a standardized heterologous HIV+ plasma, suggesting that transient viremia may have a limited impact on the intrinsic antibody-dependent functional capacity of NK cells. Overall, these observations are consistent with pediatric studies showing that controlled exposure to autologous virus, particularly with early ART initiation, can prime adaptive immune responses and confer long-term immunological benefits.29,30,33,50,51 Similarly, non-human primate models indicate that early ART, combined with structured analytical treatment interruptions (ATIs), enhances CD8+ T cell-mediated control, delays viral rebound, and reduces immune escape.30,35,52,53,54 While these studies have focused on adaptive immunity, our data suggest that innate immunity, specifically NK-mediated ADCC, may also benefit from controlled viral exposure, independently of early ART initiation. This supports a broader concept of immune training, which may act synergistically with CD8+ T cells and broadly neutralizing Abs to promote post-ART viral control. Overall, these findings extend current knowledge on antigen-driven immune modulation beyond adaptive responses, highlighting a complementary role for NK cell-mediated ADCC. If validated in larger cohorts, our findings could have important implications for HIV cure strategies, particularly those designed to enhance Fc-mediated effector functions. Indeed, antibody-dependent functions, including ADCC, are increasingly recognized as important contributors to reservoir clearance and post-treatment viral control.55,56,57,58 In this context, our results suggest that controlled antigen exposure, achieved through structured ATIs or immunotherapeutic interventions, may be associated with modulation of innate immune responses and enhanced NK cell-mediated ADCC, warranting further investigation in this setting. Limitations of the study Key limitations of this study include the relatively small sample size, requiring further validation in larger and independent cohorts. Although the observed associations were generally modest, the recurrence of similar trends across multiple experimental conditions supports the biological plausibility of the overall interpretation. The limited cohort size precluded a deep evaluation of the potential CMV contribution to NK cell functional features. Additionally, age-matching across groups was not uniform, with HC being older than PLWH, potentially affecting immune parameters. Furthermore, the cross-sectional design of the study limits the ability to assess the impact of transient viremia episodes on the NK compartment and its functions longitudinally. An additional limitation concerns the natural cytotoxicity assay, for which a target-free control condition could not be included due to limited sample availability. Finally, ADCC responses were evaluated using a single target cell model. Resource availability Lead contact Reasonable requests for further information and resources should be directed to and will be fulfilled by the lead contact, Paolo Palma (paolo.palma@uniroma2.it). Materials availability This study did not generate new unique reagents. Data and code availability •Raw anonymized ADCC flow cytometry data (.xlsx) have been deposited in Mendeley Data and are publicly available as of the date of publication. The DOI is listed in the key resources table. No additional authorization is required to access the dataset.•This paper does not report any custom code.•Any additional information required to reanalyze data reported in this paper is available from the lead contact upon reasonable request. •Raw anonymized ADCC flow cytometry data (.xlsx) have been deposited in Mendeley Data and are publicly available as of the date of publication. The DOI is listed in the key resources table. No additional authorization is required to access the dataset. Raw anonymized ADCC flow cytometry data (.xlsx) have been deposited in Mendeley Data and are publicly available as of the date of publication. The DOI is listed in the key resources table. No additional authorization is required to access the dataset. •This paper does not report any custom code. This paper does not report any custom code. •Any additional information required to reanalyze data reported in this paper is available from the lead contact upon reasonable request. Any additional information required to reanalyze data reported in this paper is available from the lead contact upon reasonable request. Acknowledgments We would like to thank all participants and legal guardians involved in these studies. We also thank Jennifer Faudella, Ilaria Pepponi, and Roberta Indaco for their administrative assistance. This work was supported by federal funds from the 10.13039/100000002NIH through the Pediatric Adolescent Virus Elimination (10.13039/100028465PAVE) Martin Delaney Collaboratory Project Number 1UM1 AI164566 (https://www.pave-collaboratory.org/, accessed on January 30, 2023) and the RV534 study (sponsored by the 10.13039/100003896Henry M. Jackson Foundation) targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines Unique Federal Award Identification Number (FAIN) U01AI135941. Additional support was provided by the ENABLE project (Early Neutralizing Antibodies in Infants Living with HIV to Enhance their Life; grant agreement number 101190620), funded by the 10.13039/100006090Global Health EDCTP3 program and co-funded by the 10.13039/501100000780European Union. Author contributions Methodology, investigation, data curation, visualization, writing – original draft, and writing – review and editing: A.R and C.P.; formal analysis, visualization, and writing – review and editing: A.P.; writing – review and editing and formal analysis supervision: G.R.P.; investigation and writing – review and editing: A.N., F.B., and S.D.C.; clinical data curation and writing – review and editing: N.C.; clinical data curation: S.B.; writing – review and editing: E.M, D.A., and M.L.; conceptualization, funding acquisition, project administration, resources, supervision, and writing – review and editing, N.C. and P.P.; all authors approved the final version for submission and agreed to be accountable for the accuracy and integrity of the manuscript. Declaration of interests The authors declare that they have no conflicts of interest and received no specific funding for this work. GRP, NC, and DA are respectively CEO and co-founders at Probiomics SRL a spin-off of the University of Rome “Tor Vergata”, which is unrelated to the present work. PP is also affiliated with Vaccinopolis, Center for the Evaluation of Vaccination and Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium. Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this work, the co-first authors used [ChatGPT by OpenAI] (https://chatgpt.com/) to improve language clarity and refine the grammar of the work. After using this tool, the co-first authors reviewed and edited the content as needed and took full responsibility for the content of the publication. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD56 PerCP-Cy5.5 (clone NCAM-1)BDCat# 560842; RRID: AB_2033964CD16 BV510 (clone 3G8)BDCat# 563830; RRID: AB_2938676CD3 Alexa Fluor 700 (clone UCHT1)BDCat# 557943; RRID: AB_396952CD3 (PE-CF594, clone UCHT1)BDCat# 562280; RRID: AB_11153674CD14 BV605 (clone M5E2)BDCat# 564054; RRID: AB_2687593CD19 BV650 (clone HIB19)BDCat# 740568; RRID: AB_2740269CD107a FITC (clone H4A3)BDCat# 555800; RRID: AB_396134CD19 APC Alexa Fluor 750 (clone SJ25-C1)BDCat# MHCD1927; RRID: AB_10373378IFN-γ BV650 (clone 4S.B3)BDCat# 56341; RRID: AB_3666114Granzyme B BV421 (clone GB11)BDCat# 563389; RRID: AB_3106190Perforin BV421 (clone δG9)BDCat# 563393; RRID: AB_2738178Cell Proliferation Dye (CPD) eFluor450eBioscienceCat# 65–0842Cell Proliferation Dye (CPD) eFluor670eBioscienceCat# 65–0840p24 PE (clone KC57-RD1)Beckman CoulterCat# 6604667; RRID: AB_1575989Biological samplesPBMCs from perinatally acquired PLWHCARMA & ITACO cohorts - Bambino Gesù Children’s Hospitalhttps://www.ospedalebambinogesu.it/about-us-169889/Plasma from perinatally acquired PLWHCARMA & ITACO cohorts - Bambino Gesù Children’s Hospitalhttps://www.ospedalebambinogesu.it/about-us-169889/Chemicals, peptides, and recombinant proteinsFicoll-Paque PLUSCytivaCat# 17144003PBSEurocloneCat# ECB4004LEDTASigmaCat# 324506-100MLFBS (fetal bovine serum)GibcoCat# 10270–106DMSO (dimethyl sulfoxide)SigmaCat# D8418RPMI 1640 mediumEurocloneCat# ECM9106LL-glutamine 100×EurocloneCat# ECB30000DPenicillin/StreptomycinEurocloneCat# ECB30001DLookout® One-Step Mycoplasma PCR Detection KitSigma-AldrichCat# MP0050-100TSTLIVE/DEAD™ Fixable Near-IR Dead Cell dyeInvitrogenCat# L34976PFA (formaldehyde)SigmaCat# HT5014-120MLGolgiStopBDCat# 51-2092KZBFA (Brefeldin A)SigmaCat# B7450TritonBioradCat# ×100-500MLFACS Permeabilizing Solution IIBD BioscencesCat# 340973Critical commercial assaysHIV Western Blot kit 2.2MP Biomedicals Germany GmbHCat# 11030–036Deposited dataRaw ADCC dataset from flow cytometry dataMendeley DataMendeley Data: https://doi.org/10.17632/tbk3n9m6y7.1Experimental models: Cell lines8E5/LAV (HIV1) cell lineNIH-ARPCat# ARP0110 RRID: CVCL_3484Software and algorithmsFlowJo (v10.10.0)Tree Star LLCN/APrism 10GraphPadN/AR (v4.4.0)R Core TeamN/AImageJ software (1.52v)NIHN/ACytExpert 2.0Beckman Coulter Life SciencesN/ABioRenderBioRenderN/AOtherCytoFLEX Flow CytometerBeckman Coulter Life SciencesN/ACountess II automated cell counterThermoFisher ScientificN/A REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD56 PerCP-Cy5.5 (clone NCAM-1)BDCat# 560842; RRID: AB_2033964CD16 BV510 (clone 3G8)BDCat# 563830; RRID: AB_2938676CD3 Alexa Fluor 700 (clone UCHT1)BDCat# 557943; RRID: AB_396952CD3 (PE-CF594, clone UCHT1)BDCat# 562280; RRID: AB_11153674CD14 BV605 (clone M5E2)BDCat# 564054; RRID: AB_2687593CD19 BV650 (clone HIB19)BDCat# 740568; RRID: AB_2740269CD107a FITC (clone H4A3)BDCat# 555800; RRID: AB_396134CD19 APC Alexa Fluor 750 (clone SJ25-C1)BDCat# MHCD1927; RRID: AB_10373378IFN-γ BV650 (clone 4S.B3)BDCat# 56341; RRID: AB_3666114Granzyme B BV421 (clone GB11)BDCat# 563389; RRID: AB_3106190Perforin BV421 (clone δG9)BDCat# 563393; RRID: AB_2738178Cell Proliferation Dye (CPD) eFluor450eBioscienceCat# 65–0842Cell Proliferation Dye (CPD) eFluor670eBioscienceCat# 65–0840p24 PE (clone KC57-RD1)Beckman CoulterCat# 6604667; RRID: AB_1575989Biological samplesPBMCs from perinatally acquired PLWHCARMA & ITACO cohorts - Bambino Gesù Children’s Hospitalhttps://www.ospedalebambinogesu.it/about-us-169889/Plasma from perinatally acquired PLWHCARMA & ITACO cohorts - Bambino Gesù Children’s Hospitalhttps://www.ospedalebambinogesu.it/about-us-169889/Chemicals, peptides, and recombinant proteinsFicoll-Paque PLUSCytivaCat# 17144003PBSEurocloneCat# ECB4004LEDTASigmaCat# 324506-100MLFBS (fetal bovine serum)GibcoCat# 10270–106DMSO (dimethyl sulfoxide)SigmaCat# D8418RPMI 1640 mediumEurocloneCat# ECM9106LL-glutamine 100×EurocloneCat# ECB30000DPenicillin/StreptomycinEurocloneCat# ECB30001DLookout® One-Step Mycoplasma PCR Detection KitSigma-AldrichCat# MP0050-100TSTLIVE/DEAD™ Fixable Near-IR Dead Cell dyeInvitrogenCat# L34976PFA (formaldehyde)SigmaCat# HT5014-120MLGolgiStopBDCat# 51-2092KZBFA (Brefeldin A)SigmaCat# B7450TritonBioradCat# ×100-500MLFACS Permeabilizing Solution IIBD BioscencesCat# 340973Critical commercial assaysHIV Western Blot kit 2.2MP Biomedicals Germany GmbHCat# 11030–036Deposited dataRaw ADCC dataset from flow cytometry dataMendeley DataMendeley Data: https://doi.org/10.17632/tbk3n9m6y7.1Experimental models: Cell lines8E5/LAV (HIV1) cell lineNIH-ARPCat# ARP0110 RRID: CVCL_3484Software and algorithmsFlowJo (v10.10.0)Tree Star LLCN/APrism 10GraphPadN/AR (v4.4.0)R Core TeamN/AImageJ software (1.52v)NIHN/ACytExpert 2.0Beckman Coulter Life SciencesN/ABioRenderBioRenderN/AOtherCytoFLEX Flow CytometerBeckman Coulter Life SciencesN/ACountess II automated cell counterThermoFisher ScientificN/A Experimental model and study participant details Study participants This study included 22 ART-treated PLWH (mean age: 14.45±6.2 years; sex: 8 males, 14 females; ethnicity: 50% black, 36.4% white, 13.6% other), who acquired the virus perinatally and exhibited undetectable viral load (VL<40 HIV RNA copies/mL) at enrollment at Bambino Gesù Children’s Hospital, IRCSS, Rome, Italy. Clinical and demographic characteristics, including age and sex distribution, are reported in Table 1. To assess the dynamics of the spontaneous RNA-expressing reservoir, plasma VL was collected every 3-6 months, during routine clinical evaluations, from ART initiation. Participants were categorized according to the total number of lifetime detectable VL episodes (0, n=9; 1, n=10; ≥2, n=3). Transient viremia was defined as a single episode of detectable plasma HIV RNA followed by renewed virological suppression at the subsequent clinical visit: blips (VL=50-200 copies/mL), spikes (VL=201-1000 copies/mL), or rebounds (VL>1000 copies/mL), whereas virological failure was defined as detectable viremia at two consecutive timepoints followed by subsequent suppression (VL>200 copies/mL on two consecutive occasions). To further characterize the temporal relationship between transient viremia and immune profiling, the time intervals between virological suppression, detectable viremia episodes, renewed suppression and sample collection were retrospectively evaluated. Episodes of transient viremia were occasionally associated with suboptimal adherence to ART reported in medical records. In addition, 4 perinatally acquired vPLWH (mean age: 22.32±4.5 years; sex: 1 male and 3 females; ethnicity: 50% black, 50% white), with a VL>200 HIV RNA copies/mL at enrollment, were later included in the analysis to explore the potential influence of intermittent viremia on the observed outcomes. A control group of 8 healthy controls (HC, mean age: 26.84±3.8 years; sex: 4 males and 4 females; ethnicity: 100% white) was also included for comparison (Table 1). Both male and female participants were included in the study. No significant differences in sex distribution were observed among the study groups. Accordingly, participants were not stratified by sex. Because of the limited sample size, the study was not designed to evaluate the influence of sex on the study outcomes. The study adhered to the Declaration of Helsinki’s principles and was approved by the local ethics committee of Bambino Gesu Children’s Hospital, Rome, Italy (EudraCT number: 2024-518694-33-00; ITACO_2780_OPBG_2022; 1463_OPBG_2017). Written informed consent was obtained from all study participants or their parents/legal guardians. Cell lines The human 8E5LAV cell line, containing a single defective HIV provirus synthetizing all major viral proteins except p64,39 was obtained from the Center for AIDS Reagents (CFAR repository, catalogue no. 0110) and used as target in functional assays. 8E5LAV cells were cultured in complete RPMI 1640 medium (cRPMI, supplemented with 10% FBS, 1% L-glutamine, 1% Penicillin/Streptomycin) at 37°C in a humidified atmosphere containing 5%CO2 and were maintained in culture for no longer than two consecutive months. Cell line identity was based on the supplier's quality control procedures and accompanying product documentation, and cells were maintained according to the supplier's recommendations. Cultures were routinely tested and confirmed to be free of mycoplasma contamination. Method details Sample collection and storage Peripheral blood mononuclear cells (PBMCs) were isolated, within 4 hours, from blood collected in ethylenediaminetetraacetic acid (EDTA) tubes by Ficoll-Paque density gradient centrifugation. Plasma was separated by centrifugation and stored at -80°C. Number of live cells were detected by the Countess II automated cell counter (ThermoFisher Scientific), then cryopreserved in fetal bovine serum (FBS) supplemented with 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. NK cell immunophenotyping Thawed PBMCs were stained with LIVE/DEAD cell dye 15’ at room temperature (RT) and then with anti CD56-PerCP-Cy5.5, CD16-BV510, CD3-Alexa Fluor700, CD14-BV605 and CD19-BV650 Abs (20’/4°C). Cells were fixed (20’/RT) with 2% formaldehyde (PFA) and resuspended in Facs Buffer (FB, PBS + 1% FBS). Flow cytometry data were analyzed using a standardized gating strategy across all samples. Doublets were first excluded based on forward and side scatter (FSC/SSC) parameters, followed by identification and gating of lymphocytes. Dead cells were then excluded. T cells (CD3+), B cells (CD19+) and monocytes (CD14+) were removed from the analysis by gating the CD3-CD19-CD14- population. Subsequently, NK cells were defined based on differential expressions of CD56 and CD16 markers. Within NK compartment, five subsets were identified according to CD56/CD16 surface expression: CD56dimCD16-, CD56brightCD16-, CD56brightCD16+, CD56dimCD16+, and CD56lowCD16+.14,17 Gating strategy is shown in Figure S1A. Antibody-dependent cellular cytotoxicity assay PBMCs were used as effectors against 8E5LAV targets with heat-inactivated (56°C/1h), 1:100 diluted, autologous (pHIVauto) or heterologous (pHIVhetero) HIV+ plasma, HIV- plasma (pHD) or without plasma as previously described.36,38 pHIVhetero, from a hyperimmune HIV+ individual with a 5.5 WB score, was used to isolate the NK cell-intrinsic component of the ADCC response. Thawed PBMCs after recovery overnight, were co-cultured with targets (1:1 ratio) in 96-well U-bottom plate and stained with anti-CD107a-FITC Ab. The plate was incubated (37°C-5%CO2) for 6 hours and BD-GolgiStop and Brefeldin-A were added after 1 hour. After stimulation, cells were washed with FB + 5 mM EDTA and stained with the LIVE/DEAD cell dye (15’/RT). Before fixation with 2% PFA (20’/RT), cells were stained (20’/4°C) with anti-CD56-PerCP-Cy5.5, CD16-BV510, CD3-PE-CF594, CD14-BV605 and CD19-APC-AlexaFluor750 Abs. Cells were then permeabilized with PBS + 2% FBS + 0.05% Triton (20’/RT) and stained (30’/4°C) with anti IFN-γ-BV650, granzyme- and perforin-BV421 Abs. Flow cytometry data were analyzed using a standardized gating strategy across all samples and experimental conditions. Doublets were first excluded based on forward and side scatter (FSC/SSC) parameters, followed by identification and gating of lymphocytes. Dead and B cells (CD19+) were then excluded, and T cells (CD3+) and monocytes (CD14+) were subsequently removed. Within the resulting CD3-CD14- population, NK cells were defined based on differential expressions of CD56 and CD16. Functional markers (CD107a, IFN-γ, and CD16) were then assessed within the NK cell gate and gating thresholds were established using unstimulated (no plasma) conditions as internal negative controls for each participant and were consistently applied across all stimulation conditions. The ADCC assay setup and gating strategy are detailed in Figure S1B. Infected cell elimination assay Infected cell elimination assays36,37,38 were performed under the same experimental conditions. Cell Proliferation Dye (CPD) eFluor450-labeled effectors were incubated with CPD eFluor670-labeled targets with plasma sources. After stimulation, cells were stained (15’/RT) with the LIVE/DEAD cell dye, fixed (20’/RT) with 1% PFA, permeabilized (20’/RT) with 1X BD FACS Permeabilizing Solution II and then stained (30’/4°C) with anti-p24-PE Ab. Flow cytometry data were analyzed using a standardized gating strategy across all samples and experimental conditions. Doublets were first excluded based on forward and side scatter (FSC/SSC) parameters, followed by identification and gating of lymphocytes. CPDeFluor670+ target 8E5LAV cells were identified within live cells, after the exclusion of CPDeFluor450+ effectors. Then, p24+ targets were gated. The % of killing was calculated using the formula: ([(% p24+ cells in targets+effectors) - (% p24+ cells in targets+effectors+plasma)] / (% p24+ cells in targets only)) x 100.36,37,38 A representative cartoon and the gating strategy are shown in Figure S1C. Western blot HIV Western Blot kit 2.2 (MP Biomedicals, Germany GmbH) was used, following the manufacturer’s instructions, to qualitatively assess reactivity patterns across Env (gp160, gp120, gp41), Gag (p55, p39, p24, p17), and Pol (p66, p51, p31) antigens, by detecting HIV-specific IgG antibodies (Abs) in 20 μL of participants’ plasma, as previously described.34,38,59 WB strips were analyzed using the ImageJ software (1.52v). A score of 1 was assigned when the intensity of the band was ≥50% of that found in the positive control for the same antigen, 0.5 when the band intensity ranged from 10% to 49%, and 0 when the band intensity ranged from 0% to 9%. A cumulative WB score was assigned to each participant by summing positive (1) and weak (0.5) responses, yielding a total score ranging from 0 to 9. Abs specific responses for each antigen are reported in Table S1. Quantification and statistical analysis Samples were acquired with CytoFLEX Flow Cytometer (Beckman Coulter) and data analyzed with FlowJo software (v10.10.0). Gating strategies were defined using unstimulated (no plasma) conditions as internal negative controls for each sample and applied uniformly across all experimental conditions. This approach allowed consistent threshold setting for functional marker expression in the absence of fluorescence minus one (FMO) controls, which were not feasible due to limited cell availability. ADCC data normalization was performed as the ratio of frequencies or mean fluorescent intensity (MFI) in stimulated versus unstimulated conditions for each sample. Given the limited sample size, all statistical analyses were conducted using non-parametric methods. For comparisons involving three independent groups, Kruskal-Wallis H test was used, followed by uncorrected Dunn’s post hoc test. Matched samples across three conditions were analyzed by the Friedman test, followed by uncorrected Dunn’s post hoc test. The Mann-Whitney and the Wilcoxon tests were used for two unpaired or paired groups comparisons respectively. Correlation analyses were assessed using Spearman’s rank correlation coefficient. Categorical variables were analyzed using Fisher's Exact Test. Statistical analyses were performed using Graph Pad Prism (v8) and R software (v4.4.0). p-value < 0.05 was considered statistically significant. ∗ 0.01 < p < 0.05; ∗∗ 0.001 < p < 0.0099; ∗∗∗ 0.0001 < p < 0.00099; ∗∗∗∗ p < 0.0001.